ARMP Armata Pharmaceuticals Inc
Price (delayed)
$1.23
Market cap
$44.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.52
Enterprise value
$156.25M
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is
Highlights
Armata Pharmaceuticals's EPS has surged by 73% YoY and by 54% QoQ
The company's net income has surged by 73% YoY and by 54% QoQ
The company's quick ratio has shrunk by 77% YoY but it has surged by 52% QoQ
The equity has contracted by 50% YoY but it has grown by 6% from the previous quarter
Key stats
What are the main financial stats of ARMP
Market
Valuations
Earnings
Shares outstanding
36.18M
Market cap
$44.51M
Enterprise value
$156.25M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
8.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.2
Revenue
$5.17M
Gross profit
$5.17M
Operating income
-$42.44M
Net income
-$18.92M
EBIT
-$8.17M
EBITDA
-$6.85M
Free cash flow
-$39.43M
Per share
Balance sheet
Liquidity
EPS
-$0.52
EPS diluted
-$0.89
Free cash flow per share
-$1.09
Book value per share
-$1.33
Revenue per share
$0.14
TBVPS
$2.29
Total assets
$86.44M
Total liabilities
$134.46M
Debt
$126.52M
Equity
-$48.02M
Working capital
-$36.94M
Debt to equity
-2.63
Current ratio
0.23
Quick ratio
0.32
Net debt/EBITDA
-16.32
Margins
Efficiency
Dividend
EBITDA margin
-132.4%
Gross margin
100%
Net margin
-365.6%
Operating margin
-820.2%
Return on assets
-18.3%
Return on equity
N/A
Return on invested capital
-7%
Return on capital employed
-21.4%
Return on sales
-158%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARMP stock price
How has the Armata Pharmaceuticals stock price performed over time
Intraday
4.24%
1 week
36.06%
1 month
-39.71%
1 year
-50.8%
YTD
-33.51%
QTD
-15.75%
Financial performance
How have Armata Pharmaceuticals's revenue and profit performed over time
Revenue
$5.17M
Gross profit
$5.17M
Operating income
-$42.44M
Net income
-$18.92M
Gross margin
100%
Net margin
-365.6%
The company's net margin has surged by 76% YoY and by 52% QoQ
The company's net income has surged by 73% YoY and by 54% QoQ
The revenue is up by 14% year-on-year but it is down by 5% since the previous quarter
ARMP's gross profit is up by 14% year-on-year but it is down by 5% since the previous quarter
Growth
What is Armata Pharmaceuticals's growth rate over time
Valuation
What is Armata Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
8.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.2
Armata Pharmaceuticals's EPS has surged by 73% YoY and by 54% QoQ
The equity has contracted by 50% YoY but it has grown by 6% from the previous quarter
ARMP's price to sales (P/S) is 94% lower than its 5-year quarterly average of 155.5 and 61% lower than its last 4 quarters average of 21.9
The revenue is up by 14% year-on-year but it is down by 5% since the previous quarter
Efficiency
How efficient is Armata Pharmaceuticals business performance
Armata Pharmaceuticals's return on sales has surged by 89% YoY and by 73% QoQ
ARMP's return on invested capital has surged by 86% year-on-year and by 73% since the previous quarter
Armata Pharmaceuticals's ROA has soared by 72% YoY and by 53% from the previous quarter
Dividends
What is ARMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARMP.
Financial health
How did Armata Pharmaceuticals financials performed over time
ARMP's total assets is 36% lower than its total liabilities
ARMP's current ratio has dropped by 80% year-on-year but it is up by 21% since the previous quarter
The company's quick ratio has shrunk by 77% YoY but it has surged by 52% QoQ
The equity has contracted by 50% YoY but it has grown by 6% from the previous quarter
ARMP's debt to equity is up by 30% year-on-year and by 4.4% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.